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ABSTRACT

Disclosed herein are compounds useful in inhibiting the
action of AB-type bacterial toxins such as cholera, traveler's
diarrhea, enterohemorrhagic diarrhea caused by E. coli 0157:
H7 and pertussis or whooping cough. Also included in the
invention is the use of these compounds in treatment of diseases associated with those toxins.
17 Claims, 26 Drawing Sheets
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METHOD OF INHIBITING AB-TYPE
BACTERIAL TOXINS AND TREATMENT FOR
ASSOCIATED DISEASES

Toxin Dislocation and Cellular Intoxication" provides proofof-principle for an anti-toxin therapeutic strategy that blocks
the thermal unfolding of the toxin A chain. This paper was
filed as part of the provisional application to which priority is
claimed herein. As demonstrated in this experimental work,
which is further expanded below, the inhibition of A chain
unfolding prevents toxin passage into the cytosol and, hence,
prevents productive intoxication.
Also further detailed below are data from our study entitled
"Hsp90 is Required for Transfer of the Cholera Toxin Al
Subunit from the Endoplasmic Reticulum to the Cytosol."
These data demonstrate that geldanamycin (GA), an inhibitor
of heat shock protein 90 (Hsp90), blocks toxin passage into
the cytosol, also blocking productive intoxication. This
experimental work shows that (i) Hsp90 binds directly to the
catalytic CTAl subunit with high affinity; (ii) GA blocks the
binding of Hsp90 to CTAl; (iii) GA blocks CTAl passage
from the endoplasmic reticulum (ER) to the cytosol; and (iv)
GA blocks CT intoxication in cultured cells and in the physiological ilea! loop model of toxin-induced diarrhea. We have
found that GA is effective in blocking CT intoxication in
cultured cells at a level of0.1 µM.
We have also now shown that sodium 4-phenylbutyrate
(PBA) blocks CT activity against cultured cells in a dosedependent manner. Additionally, we have shown that PBA
blocks CTAl export to the cytosol. One of our collaborating
laboratories has reported that PBA also blocks CT activity in
the ilea! loop test system. As with ricin and exotoxin A,
neither GA nor PBA have, so far, shown to inhibit Shiga toxin
activity against cultured cells.
Yet additionally, we have generated preliminary evidence
that both GA and PBA will be effective against pertussis toxin
(PT). We have shown that Hsp90 binds to the catalytic subunit
of PT (PTS 1) in anATP-dependent manner that is inhibited by
GA. We have also shown that PBA inhibits the thermal
unfolding of PTSl. Intoxication assays with PT and GA or
PBA remain to be completed.
PBA is an FDA approved drug. The maximal FDA
approved dose of PBA for therapeutic use is 20 g/d, which
produces PBA serum levels between 600 and 1, 700 uM. This
is from oral administration of four 500 mg tablets over the
course of a day. We have shown that PBA is effective against
CT intoxication of cultured cells at a concentration ranging
from 10-100 µM. This concentration is well below the maximum permissible serum level of PBA. In addition, as noted
above, a dose of 20 g/d produces serum levels of PBA
between 600 and 1,700 uM, however, it is not necessary to
deliver PBA to the serum, but only that it be present in the
intestines, which is where it would be delivered by oral
administration. Thus, an effective dose of PBA is deliverable
to the intestinal epithelium with a drug concentration far
below the maximal dosage. Two published papers that have
reported PBA as a therapeutic "chemical chaperone" for
treating genetic diseases are by A. F. Collins et al., "Oral
sodium phynylbutyrate therapy in homozygous beta thalassemia: a clinical trial"; Blood, 1995, 85:43-49; and Jeffrey H.
Teckman, "Lack of effect of oral 4-phenylbutyrate on seum
alpha-1-antitrypsin in patients with a-1-antitrypsin deficiency: a preliminary study"; J. Ped. Gastroenterology and
Nutrition, July 2004, 39:34-37. These two papers report PBA
serum levels between 600 and 1,700 uM.

RELATED APPLICATION

5

This application claims priority from provisional application Ser. No. 61/086,918, which was filed on 7 Aug. 2008 and
which is incorporated herein by reference in its entirety.
10

STATEMENT OF GOVERNMENT RIGHTS
The invention claimed herein was made with at least partial
support from the U.S. Government through NIH grants ROI
AI073783, K22 AI054568 and R03 AI067987 to K. Teter.
Accordingly, the goverrnnent may have certain rights in the
invention, as specified by law.

15

FIELD OF THE INVENTION
20

This invention relates to infectious diseases and, more
specifically, to inhibitors ofbacterial toxins of the type having
a catalytic A subunit and a cell-binding B subunit and, especially to those within this group which function as ADPribosylating toxins.

25

BACKGROUND OF THE INVENTION
Bacterial toxins have been known to be primary mediators
of a number of diseases both of the intestinal tract and of other
organ systems. Some bacterial toxins are known as AB-type
toxins, since they are composed of a catalytic A subunit and a
cell-binding B subunit. Examples of such AB-type toxins
include cholera toxin (CT), the E. coli heat-labile toxin (LT)
responsible for traveler's diarrhea, the B. pertussis toxin
responsible for much of the symptomatology of whooping
cough, exotoxin-A produced by Pseudomonas aeruginosa
strains often found in the respiratory tract of cystic fibrosis
patients or on the damaged skin of burn patients, Shiga toxin
produced in the intestinal disease shigellosis, and the similar
toxin produced by enterohemorrhagic E. coil and which has
lately been associated in the U.S. with contaminated produce
and ground beef products.
Typically, the diseases caused by these bacterial toxins are
treated symptomatically because drugs effective against the
toxins themselves have not been available. Except in the case
of pertussis, prior immunizations have either not been available or have not been very successful in conferring a protective immunity against these toxins.
Accordingly, there is a great need for drugs that would act
directly against these toxins, interfering with their mechanisms of action so as to prevent entry of the active toxin into
targeted host cells and cellular intoxication. The present
invention provides such long-needed drugs and discloses a
proposed new model mechanism by which extracellular ABtype toxins gain access to the affected cells of the body.

30
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SUMMARY OF THE INVENTION
With the foregoing in mind, the present invention advantageously provides a new understanding of the mechanisms
of action of AB-type bacterial toxins at the cellular level and
identifies compounds which are able to block these toxins'
biologic activity, consequently, the compounds are useful in
methods of treatment of the respective diseases.
Our soon to be published paper titled "Stabilization of the
Tertiary Structure of the Cholera Toxin Al Subunit Inhibits

60

BRIEF DESCRIPTION OF THE DRAWINGS
65

Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunc-
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tion with the accompanying drawings, presented for solely
for exemplary purposes and not with intent to limit the invention thereto, and in which:
FIG. 1 shows stability curves for the catalytic CTAl subunit in the absence or presence of sodium 4-phenylbutyrate
(PBA), as demonstrated by near-UV circulardichroism (CD),
fluorescence spectroscopy, and far-UV CD (from left to right,
respectively, in the figure);
FIG. 2 demonstrates lowered CT toxicity to cells in culture
when the cells are treated with geldanamycin (GA);
FIG. 3 is a line graph showing the effect of PBA treatment
on the cellular toxicity of up to 10 ng/ml CT;
FIG. 4 provides the same comparison as FIG. 3, except the
CT concentration is extended up to 100 ng/ml;
FIG. 5 is another line graph comparing the effect of no
treatment (control), treatment with geldanamycin and treatment with PBA on cell toxicity caused by exotoxin A (ETA)
of Pseudomonas aeruginosa;
FIG. 6 compares cell toxicity due to ricin when the cells are
untreated (control), treated with geldanamycin and treated
withPBA;
FIG. 7 shows that glycerol prevents the temperature-induced conversion ofCTAl to a protease-sensitive conformation: (a): 1 mg samples of the CTA1/CTA2 heterodimer were
exposed to lOmM ~-ME for 5 minin the absence or presence
of 10% glycerol before loading on a non-reducing SDSPAGE gel; 1 mg of a CTA1/CTA2 heterodimer that was not
exposed to ~-ME was also run on the gel; samples were
visualized by Coomassie staining, which does not detect the
dissociated 5 kDa CTA2 subunit; (b ): samples of the reduced
CTA1/CTA2 heterodimer were placed in 20 mM sodium
phosphate buffer (pH 7.0) lacking or containing 10% glycerol; after incubation at the stated temperatures for 1 hr, the
samples were shifted to 4° C. and exposed to thermolysin for
1 hr at 4° C.; samples were visualized by SDS-PAGE and
Coomassie staining;
FIG. 8 shows thermal stabilization of CTAl by glycerol:
(a-d): the temperature-induced unfolding of a purified, His6tagged CTAl protein in the absence (a-b) or presence (c-d) of
10% glycerol was monitored by near-UV CD (a, c) and farUV CD (b, d); both measurements were conducted nearsimultaneously on the same sample after equilibration at each
temperature for 4 min; measurements were taken with a
4-mm optical path-length rectangular quartz cuvette at a protein concentration of 73 mg/ml in 20 mM sodium borate
buffer (pH 7.4) containing 150 mM NaCl; the change in color
from blue to red corresponds to a change in temperature from
18° C. to 65° C.; (e-f): depicts thermal unfolding profiles for
CTA1-His6 in the absence (red) or presence (blue) of 10%
glycerol were derived from the data presented in panels a-d;
(e): for near-UV CD analysis, the mean residue molar ellipticities at 280 nm ([8]280) were plotted as a function of
temperature; (f): for far-UV CD analysis, the mean residue
molar ellipticities at 220 nm ([8]220) were plotted as a function of temperature;
FIG. 9 illustrates that glycerol treatment blocks CTAl dislocation from the ER; HeLa cells were pulse-labeled at 4 ° C.
for 30 min with 1 mg/ml of CT; the cells were then chased for
2 hr at 37° C. in toxin-free medium that either lacked or
contained 10% glycerol; selective permeabilization of the
plasma membrane with digitonin was used to partition cell
extracts into separate membrane (pellet; P) and cytosolic
(supernatant; S) fractions; (a): both fractions were probed by
Western blot to establish the distributions of cytosolic marker
Hsp90, ER marker PDI, and CTAl; one of two representative
experiments is shown; (b ): a sensor slide coated with an
anti-CTA antibody was used to detect the cytosolic pool of

CTAl from untreated (no treatment) or glycerol-treated
(+glycerol) cells by SPR; CTA standards (10 ng/ml and 1
ng/ml) were perfused over the sensor slide as positive controls; cytosolic fractions from unintoxicated cells and cells
intoxicated in the presence ofbrefeldin A (+BfA) were also
generated for this experiment; one of four representative
experiments is shown; the arrow indicates when the sample
was removed from the perfusion buffer; at the end of each
experiment, bound sample was stripped from the sensor slide
with a 5 min PBST wash at pH 6.0;
FIG. 10 indicates that glycerol treatment stimulates CTAl
secretion from intoxicated cells; HeLa cells pulse-labeled at
4 ° C. for 30 min with 1 mg/ml of CT were chased for 2 hr at
37° C. in toxin-free medium that lacked (no treatment) or
contained 10% glycerol (+glycerol); media samples from
these cells and from unintoxicated control cells were then
analyzed by SPR with a sensor slide that had been coated with
an anti-CTA antibody; CTA standards ( 10 ng/ml and 1 ng/ml)
were also perfused over the sensor slide as positive controls;
one of four representative experiments is shown, the arrow
indicates when the sample was removed from the perfusion
buffer; at the end of each experiment, bound sample was
stripped from the sensor slide with a 5 min PBST wash at pH
6.0;
FIG. 11 depicts that CTAl secretion from intoxicated cells
occurs in a time-dependent process that is inhibited by BfA;
(a-b): HeLa cells pulse-labeled at 4° C. for 30 min with 1
mg/ml of CT were chased for 30, 60, 90, or 120 min at 3 7° C.
in toxin-free medium that lacked (a) or contained (b) 10%
glycerol; media samples from these cells, from intoxicated
cells chased for 120 min in the presence of 5 mg BfA/ml (120
min+BfA), and from unintoxicated control cells were then
analyzed by SPR with a sensor slide that had been coated with
an anti-CTA antibody; CTA standards ( 10 ng/ml and 1 ng/ml)
were also perfused over the sensor slide as positive controls;
the arrow indicates when the sample was removed from the
perfusion buffer; at the end of each experiment, bound sample
was stripped from the sensor slide with a 5 min PBST wash at
pH 6.0; (c): to approximate the amount of CTAl secreted
from intoxicated cells, association rate constants were calculated from the SPR data obtained for the secreted pools of
CTAl and forthe ten-fold serial dilutions of purified CTA that
were perfused over the CTA sensor slide; the association rate
constants for the CTA standards were plotted as a function of
protein concentration (n=3; averages±standard deviations are
shown); the slope of the resulting standard curve was then
used to calculate the concentration of CTAl in untreated and
glycerol-treated media samples; the means±standard errors
of the means of five independent experiments are shown;
CTA standards are presented as diamonds; untreated media
samples are presented as an open square; and glycerol-treated
media samples are presented as an open circle;
FIG. 12 shows that glycerol does not inhibit the dissociation of CTAl from CTA2/CTB5; after appending CT to an
SPR sensor slide, a baseline measurement corresponding to
the mass of the holotoxin was recorded; reduced PDI was then
perfused over the CT-coated sensor slide in the presence of
10% glycerol; PDI was present in the perfusion buffer for the
duration of the experiment; an anti-CTA antibody was also
added to the perfusion buffer 420 sec into the experiment;
FIG.13 indicates that glycerol treatment interferes with CT
intoxication; CHO cells were incubated for 2 hrs with varying
concentrations of CT in media lacking (circles) or containing
(squares) 10% glycerol; cAMP levels were then assessed with
the use of an [ 125 I]-cAMP competition assay; results
(means±SEMs of 4 independent experiments with triplicate
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samples) are expressed as percentages of the maximal CT
response for all tested conditions;
FIG. 14 presents data that glycerol inhibits CTAl degradation by the 20S proteasome; (a): reduced CTA1/CTA2 heterodimers were incubated at 37° C. with 100 nM of the 20S
proteasome in the absence or presence of 10% glycerol;
samples taken at the indicated time points were visualized by
SDS-PAGE and Coomassie staining; (b ): an identical protocol was followed with a-casein as the sample protein;
FIG. 15 shows how glycerol blocks the time-dependent
appearance of CTAl in the cytosol; HeLa cells were pulselabeled at 4 ° C. for 30 min with 1 mg/ml of CT; the cells were
then chased for 1, 2, 3, 4, or 5 hr at 37° C. in toxin-free
medium that lacked or contained 10% glycerol; selective
permeabilization of the plasma membrane with digitonin was
used to partition cell extracts into separate membrane and
cytosolic fractions; an SPR sensor slide coated with an antiCTA antibody was used to detect the cytosolic pools ofCTAl
from untreated (green lines) or glycerol-treated (red lines);
CTA standards (10 ng/ml, 1 ng/ml, and0.1 ng/ml; black lines)
were perfused over the sensor slide as positive controls; a
cytosolic fraction from unintoxicated cells (blue line) was
also generated for this experiment; a small pool of CTAl was
detected in the cytosol of untreated cells after 1 hr of chase;
the amount of cytosolic CTAl increased after 2 hr of chase
and remained constant over 3 and 4 hr of chase; after five
hours of chase, an additional increase in cytosolic CTAl was
detected; no cytosolic pool of CTAl was detected at any time
point for the glycerol-treated cells; at the end of each experiment, bound sample was stripped from the sensor slide with a
PBST wash at pH 6.0;
FIG. 16 shows CTAl secretion from Vero cells; Vero cells
pulse-labeled at 4° C. for 30 min with 1 mg/ml of CT were
chased for 2 hr at 37° C. in toxin-free medium that lacked (no
treatment) or contained 10% glycerol (+glycerol); a separate
set of intoxicated cells were chased in medium that contained
either 5 mg/ml of BfA ( +BfA) or both 10% glycerol and 5
mg/ml of BfA (+glycerol & BfA); media samples from the
intoxicated cells and from unintoxicated control cells were
then analyzed by SPR with a sensor slide that had been coated
with an anti-CTA antibody; CTA standards (10 ng/ml and 1
ng/ml) were also perfused over the sensor slide as positive
controls; the arrow indicates when the sample was removed
from the perfusion buffer; at the end of each experiment,
bound sample was stripped from the sensor slide with a 5 min
PBST wash at pH 6.0;
FIG. 17 indicates that GA but not N-ethylcarboxamidoadenosine (NECA) inhibits the interaction between CTAl and
Hsp90; either Hsp90 (a) or GRP94 (b) was perfused over a
CTAl-coated SPR sensor slide under the following conditions: no ATP in the perfusion buffer, 1 mM ATP in the
perfusion buffer, 1 mMATP and 0.1 mM GA in the perfusion
buffer, or 1 mM ATP and 0.1 mM NECA in the perfusion
buffer; Hsp90 and GRP94 were used at 100 mg/ml concentrations; arrowheads denote the time point at which the ligand
was removed from the perfusion buffer; one of several representative experiments is shown; in panel b, the *** indicates
all experimental conditions other than GRP94+ATP;
FIG. 18 shows binding of CTAl to Hsp90 or GRP94;
Hsp90 (a) or GRP94 (b) were perfused over a CTAl-coated
SPR sensor slide at 100, 400, 800, 1,600, and 3,200 nM
concentrations; (b ): GRP94 was perfused over a CTAlcoated SPR sensor slide at concentrations of 100, 400, 800,
and 1,600 nM; note that the results for Hsp90 and GRP94 are
plotted on different scales; for all conditions, 1 mMATP was
present in the perfusion buffer; measurements were performed in three independent experiments with three different

CTAl sensor slides; all the collected data are shown; the red
lines represent best fit curves derived from the raw data using
1:2 (CTAl :Hsp90 orCTAl :GRP94) binding models; the SPR
traces display, from the top to the bottom of the graph, results
for decreasing concentrations of the ligand;
FIG. 19 GA but not NECA inhibits CT intoxication; (a):
CHO cells were incubated with varying concentrations of CT
in the absence of additional treatment, in the presence of0.1
mM GA, or in the presence of 0 .1 mM NECA; after two hours
of continual toxin exposure, toxicity was assessed from the
elevated levels of intracellular cAMP; the averages±standard
errors of the means of at least four independent experiments
with triplicate samples are shown; (b): CHO cells were incubated for 4 hours with varying concentrations of ricin in the
absence or presence of 0.1 mM NECA; toxicity was then
determined from the incorporation of [35 S]methionine into
newly synthesized proteins; the averages±ranges of two independent experiments with triplicate samples are shown; (c):
mock/CT/CT +GA/GA/forskolin/forskolin +GA;
FIG. 20 shows that GA also inhibited CT activity in the
ilea! loop model of intoxication; surgically sealed sections of
intestine were injected with 1 mg of CT in the absence or
presence of GA; hours later, the CT-injected loop displayed
the distended morphology indicative of water accumulation
resulting from productive intoxication; in contrast, loops that
were injected with both CT and 1 or 5 uM GA exhibited a
minimal amount of fluid accumulation and intestinal distension; while GA derivatives have been evaluated by others as
anti-cancer agents in phase I clinical trials, the protective
effect of GA in a physiological model of intoxication is
strongly suggestive that it could also be used as a therapeutic
to prevent or treat cholera;
FIG. 21 shows that 4-phenylbutyric acid (PBA) and
geldanamycin (GA) prevent the catalytic subunit of cholera
toxin (CTAl) from entering the cytosol of target cells; HeLa
cells were pulse-labeled at 4 ° C. for 30 min with 1 mg/ml of
CT; the cells were then chased for 2 hr at 37° C. in toxin-free
medium or toxin-free medium that contained either PBA,
GA, NECA, or brefeldinA (BfA); selective permeabilization
of the plasma membrane with digitonin was used to partition
cell extracts into separate membrane and cytosolic fractions;
a surface plasmon resonance (SPR) sensor slide coated with
an anti-CTA antibody was used to detect the cytosolic pools
ofCTAl; CTA standards (1 ng/ml and 0.1 ng/ml) were perfused over the sensor slide as positive controls, and the cytosolic extract from unintoxicated cells was perfused over the
slide as a negative control; an increase in the SPR response
signal indicates ligand binding to the plate; these data demonstrate that less CTAl was found in the cytosol of PBA- or
GA-treated cells than in the cytosol of cells chased in the
absence of drug treatment; NECA, a drug that inhibits GRP94
but not Hsp90, did not inihbit the appearance of CTAl in the
cytosol; BfA is a (toxic) drug known to inhibit toxin trafficking to the ER, and, thus, toxin passage into the cytosol; at the
end of each experiment, bound sample was stripped from the
sensor slide with a PBST wash at pH 6.0;
FIG. 22 shows how 4-phenylbutyric acid (PBA) inhibits
cholera intoxication in a dose-dependent manner; CHO cells
were incubated with varying concentrations of cholera toxin
(CT) in the absence of additional treatment or in the presence
of the indicated PBA concentrations; after 2 hours of continual toxin exposure, toxicity was assessed from the elevated
levels of cAMP;
FIG. 23 presents data showing the Hsp90 inhibitor
geldanamycin (GA) blocks the interaction between Hsp90
and the catalytic A subunit of pertussis toxin (PTS 1); surface
plasmon resonance (SPR) was used to characterize the inter-
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action between Hsp90 and PTSl; an increase in the Micro
Refractive Index Units (Micro RIU) is indicative of a physical
interaction between two proteins; Hsp90 was perfused over
an PTS I-coated SPR sensor slide under the following conditions: no ATP in the buffer, ATP in the buffer, or both GA and
ATP in the buffer; the binding ofHsp90 to client proteins is an
ATP-dependent process; the lack of interaction between
Hsp90 and PTS 1 in the absence of ATP or in the presence of
GA demonstrates the specificity of the protein-protein interaction;
FIG. 24 shows the thermal stabilization of the catalytic
subunit of pertussis toxin (PTSl) by 4-phenylbutyric acid
(PBA); (A-D): the temperature-induced unfolding of PTS 1 in
the absence (A-B) or presence (C-D) of 0.1 mM PBA was
monitored by far-UV CD (A, C) and near-UV CD (B, D); the
change in color from blue to red corresponds to a change in
temperature from 18° C. to 65° C.; (E-F): thermal unfolding
profiles for PTSl in the absence (red) or presence (blue) of
PBA were derived from the data presented in panels A-D; (E):
for far-UV CD analysis, the mean residue molar ellipticities
at 220 nm ([8]220) were plotted as a function of temperature;
(F): for near-UV CD analysis, the mean residue molar ellipticities at 280 nm ([8]280) were plotted as a function of
temperature; and
FIG. 25 resents data indicating that geldanamycin (GA)
and 4-phenylbutyric acid (PBA) do not protect cultured cells
against Shiga toxin; Vero cells expressing a destabilized variant of green fluorescent protein (tl/2=2 hr) were exposed to
Ham's F-12 medium containing tenfold dilutions of culture
supematants from Shiga toxin-producing E. coli 0157 strain
RM1697; cells were challenged with toxin in the absence of
additional treatment, in the presence of 0.1 mM GA, in the
presence of 100 mM PBA, or in the presence of both 0.1 mM
GA and 100 mM PBA; after 16 hr of intoxication, fluorescent
output was recorded with a plate reader; Shiga toxin inhibits
protein synthesis, so intoxicated cells will degrade the destabilized green fluorescent protein and will not produce more of
the protein, which thus generates a decrease in the fluorescent
signal; the fluorescent output from cells not exposed to toxin
was used to establish the maximal signal, and all other results
were expressed as a percentage of this signal; the
averages±standard errors of the means of four independent
experiments with six replicate samples for each condition are
shown.

are provided so that this disclosure will be thorough and
complete, and will fully convey the scope of the invention to
those skilled in the art. Other features and advantages of the
invention will be apparent from the following detailed
description, and from the claims.
Our paper published in Journal of Molecular Biology,
(2007) 3 7 4, 1114-1128 presents the first experimental data
demonstrating that isolated cholera toxin Al polypeptide
(CTAl) is a thermally unstable protein. CTAl is held in a
stable conformation by its association with CTA2/CTB5, but
it can spontaneously unfold at physiological temperature
when separated from the holotoxin in the endoplasmic reticulum (ER). We have proposed a new model ofCTAl translocation from the ER in that this spontaneous unfolding event
triggers the endoplasmic reticulum-associated degradation
(ERAD) system to mediate CTAl export to the cytosol. In
contrast, the currently accepted model of CTAl translocation
treats CTAl as a stable protein that requires chaperone-mediated unfolding in the ER. The current model also propounds
that CTAl stability provides the driving force for extraction
from the ER, that is, the old model holds that as unfolded
CTAl emerges from the Derlin-1 channel, it spontaneously
refolds in the cytosol and thereby gains directionality for its
movement across the ER membrane because the refolding
would prevent it from sliding back into the channel. However,
in our newly proposed model, because CTAl is actually in an
unfolded conformation at 37° C., we hypothesize that a cytosolic chaperone must provide the driving force for CTAl
export from the ER. Accordingly, under our new model, stabilization of the heat-labile CTAl polypeptide within the ER
could prevent its ERAD-mediated export to the cytosol and,
consequently, could also prevent CT intoxication. Furthermore, based on our new model, CT passage into the cytosol
and cellular intoxication could also be prevented by inhibition
of the cytosolic chaperone that provides the driving force for
CTAl export from the ER.
Additionally, our soon to be published paper titled "Stabilization of the Tertiary Structure for the Cholera Toxin Al
Polypeptide Inhibits Toxin Dislocation and Cellular Intoxication" presents proof-of-principle for the concept of our new
model. We used glycerol, a known "chemical chaperone" that
stabilizes protein structures, to inhibit the thermal unfolding
ofCTAl. Glycerol also prevented CTAl export to the cytosol
(results not shown) and CT intoxication. However, glycerol is
not a viable therapeutic option since it would be toxic to the
patient. We therefore undertook a search for non-toxic potentially effective drugs (see also, Perlmutter, D. H., Chemical
Chaperones: A Pharmacological Strategy for Disorders of
Protein Folding and Trafficking, Pediatric Research, 52(6),
832-836).
Our search identified sodium 4-phenylbutyrate (PBA) as a
potential non-toxic drug candidate. PBA, like glycerol, is
another chemical chaperone but it is tolerated by humans and
is actually an FDA-approved drug for treating diseases
related to urea cycle enzyme deficiencies. Our experimental
work disclosed in the priority provisional application (document titled "A Therapeutic Chemical Chaperone Inhibits
Cholera Intoxication and Unfolding/Translocation of the
Cholera Toxin Al Subunit'') showed that PBA prevents the
thermal unfolding ofCTAl and also prevents CT intoxication
of cultured cells. Experiments now underway, we predict will
show that PBA prevents CTAl export from the ER into the
cytosol.
Since we hypothesize that this drug may have real therapeutic potential for treating CT, and possibly other toxinmediated diseases, we are further investigating if it also demonstrates a CTAl inhibitory effect in a physiological model of

5

10

15

20

25

30

35

40

45

DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENT
The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, and other references mentioned in this application are incorporated herein by reference in their entirety. In
case of conflict, the present specification, including any definitions, will control. In addition, it should be understood that
the materials, methods and examples given are illustrative in
nature only and not intended to be limiting. Accordingly, this
invention may be embodied in many different forms and
should not be construed as limited to the illustrated embodiments set forth herein. Rather, these illustrated embodiments
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intoxication-the ilea! loop system. If, as expected, PBA
blocks intoxication in ilea! loops, this would provide strong
support for our new proposed mechanism of action of CTAl
and how this toxin may be counteracted.
A second anti-toxin therapeutic agent we have identified is
geldanamycin (GA), an inhibitor ofhsp90. GA has received a
attention as a potential anti-cancer agent (see the review
article by Blagosklonny, M. V., Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs, Leukemia (2002) 16, 456,462). GA itself was initially found to be
too toxic for therapeutic use, but second generation GA
derivatives have proven effective in phase I clinical trials. We
theorized that because hsp90 is required for the endosometo-cytosol translocation of diphtheria toxin and the clostridial
ADP-ribosylating toxins, GA might provide a good target for
a therapeutic drug. See the following: Ratts et al., The cytosolic entry of diphtheria toxin catalytic domain requires a host
cell cytosolic translocation factor complex, J. Cell Biol., 160
(7), 1139-1150 (2003); Haug et al., The Host Cell Chaperone
Hsp90 Is Essential for Translocation of the Binary
Clostridium botulinum C2 Toxin into the Cytosol, J. Biological Chem., 278(34), 32266-32274 (2003); Haug et al., The
Host Cell Chaperone Hsp90 Is Necessary for Cytotoxic
Action of the Binary Iota-Like Toxins, Infection and Immunity, 72(5), 3066-3068 (2004); and Marissa V Powers and
Paul Workman, Targeting of multiple signaling pathways by
heat shock protein 90 molecular chaperone inhibitors, Endocrine-Related Cancer (2006) 13 S125-S135.
Moreover, we have now shown by surface plasmon resonance (SPR) that hsp90 interacts directly with CTAl and that
this interaction is inhibited by GA. CT intoxication is also
blocked in GA-treated cells (attached). We are further
improving the translocation assay to determine if GA prevents the ER-to-cytosol export of CTAl. We theorize that
Hsp90 is the cytosolic chaperone that provides the driving
force for extraction of CTAl and other ADP-ribosylating
toxins from the ER.
The data shown graphically in FIG. 1 also help to explain
Table 1. The data in FIG. 1 are raw measurements from three
biophysical techniques, near-UV circular dichroism (CD),
fluorescence spectroscopy, and far-UV CD (from left to right,
respectively, in the figure). Near-UV CD and fluorescence
spectroscopy provide two different measures of protein tertiary structure. Far-UV CD provides a measurement of secondary structure. Certain linear arrangements of amino acids
will spontaneously assume common shapes known as a-helices and ~-sheets. These shapes are the secondary structure
of a protein. The linear order of amino acids is the primary
structure. The overall three dimensional structure of a protein
which is ordered around the secondary structures is the protein tertiary structure. In the tertiary structure of a properly
folded protein, the hydrophobic amino acids should be buried
within the protein and protected from the aqueous environment. The measurements of tertiary structure detect the solvent exposure of the hydrophobic amino acids; this is indicative of protein unfolding. Each line in the raw data shown in
FIG. 1 (top 6 panels) represents a measurement at a different
temperature, with the color shift from blue to red corresponding to a shift in temperature from 18 to 65° C. The top row
presents measurements taken forthe catalytic Al polypeptide
of cholera toxin (CTAl), and the middle row are measurements taken for CTAl in the presence of 100 µM PBA. The
bottom row is an analysis of the top two rows in which protein
unfolding is plotted as a function of temperature. Low Y axis
values represent folded conformations of the toxin, while
high Y axis measurements represent unfolded conformations
of the toxin. The high values plateau when the final unfolded

state is reached. From these sigmoidal curves, we can calculate how much initial protein structure remains at each temperature. The point at which 50% of the initial structure is lost
is called the transition temperature (Tm). It is the Tm values
that are listed in the Table. The Figure of the raw data and
unfolding curves only shows the data for 100 µM PBA, but we
also ran experiments for 1 and 10 µM PBA. The processed
data for these experiments are in the Table, which shows there
is some stabilization of all
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Melting temperature (Tml
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(PBAinµM)

10
100

0

NearUV(°C.)

Far UV ( 0 c.)

Fluorescence
(c C.)

33.0
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35.0
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36.0

20
0-in the absence of PBA

25

30

35

40

45

50

55

60

65

three CTAl structural parameters even at 1 µM PBA. Higher
PBA concentrations provide a higher level of structural stabilization, meaning higher temperatures are required to
unfold CTAl. Interestingly, even in the presence of PBA the
Tm values are still near physiological temperature. Given that
even 1 µM PBA has some inhibitory effect on CT intoxication, this must mean that substantial unfolding of CTAl is
required to trigger its export to the cytosol where its target
resides.
The graphs shown in FIG. 1 plot the cellular effect of CT
intoxication. CT-treated cells generate elevated levels of
cAMP which we measure. The maximal cAMP response for
all conditions is set at 100%, and all other cAMP values are
expressed as a percentage of this maximal value. Cells are
treated with toxin for 2 continual hours before measurement,
and PBA is added simultaneously with the toxin. The first
graph is the result with 1 µM PBA, and the second graph is the
result with 100 µM PBA. The control curves (results without
PBA) differ from the two graphs because two different assay
kits forusedforthe experiments, and the second kit (with 100
µM PBA) has a better detection range. We are now standardizing all of our experiments by just using the second kit.
Fold-resistance is determined from the half-maximal effective concentrations (toxin concentration that gives an effect
50% of the maximum). For 1 µMPBA, we seea3.5-foldlevel
of toxin resistance. We can't calculate fold resistance for 100
µM PBA because in the presence of PBA we didn't reach a
50% value even at the highest toxin concentration. So 100 µM
PBA works pretty well, at least in cell culture.
We have also conducted additional experiments to determine the binding affinity of PBA for CTAl. Although not
shown here, the data indicate that PBA binds to CTAl and the
CT holotoxin (which would include CTAl), but it does not
bind to the cell-binding B subunit of CT. Accordingly, there is
some specificity to the toxin-PBA interaction, which is unexpectedly surprising. PBA appears to bind to CTAl/CT with
-100 µM affinity, which represents a very high affinity interaction (tight binding).
Accordingly, this disclosure teaches that at least these two
therapeutics, PBA and GA, are effective in suppressing entry
of an AB-type bacterial toxin, particularly anADP-ribosylating toxin such as CTAl into the host cell cytosol and also
mitigates or prevents toxicity to the cells themselves. Additionally, given the high degree of similarity between CT and
E. coli LT we believe that in a prophetic example we can
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predict that PBA and GA may also be effective in blocking LT
intoxication. Moreover, we also theorize it will be fruitful to
test a combination of both PBA and GA. Since PBA and GA
block separate steps in the translocation process, they may
have an additive effect on toxin inhibition.
The toxins/diseases which we initially expected might be
inhibited by GA and/or PBA included the following:
1. cholera toxin/cholera;
2. E. coli heat-labile toxin/traveler's diarrhea;
3. pertussis toxin/whooping cough;
4. exotoxin A/infections with Pseudomonas aeruginosa
(particularly in cystic fibrosis patients or in burn victims); and
5. Shiga toxin/shigellosis and food-borne outbreaks of
enterohemorrhagic E. coli (0157 :H7).
The order shown for the toxins listed is the expected order
of likelihood for drug-induced toxin resistance. GA inhibits
Hsp90 function, and Hsp90 may specifically recognize and
interact with ADP-ribosylating toxins. CT and LTare very
similar ADP-ribosylating toxins, so that PBA and GA should
work against both of them. Pertussis toxin is anADP-ribosylating toxin and is very unstable, so there is a reasonable basis
for expecting that both PBA and GA will work against this
toxin.
Our experiments with exotoxinA (ETA) only showed weak
drug-induced resistance, although we still need to test the
PBA/GA combination treatment. ETA is also an ADP-ribosylating toxin, so we expected GA to work against it. The
stability of ETA is unknown, but our new model predicts all
AB-type (catalytic A subunit, cell-binding B subunit) ERtranslocating toxins will have an unstable A chain.
Shiga toxin is not an ADP-ribosylating toxin, thus, we
expected a lower probability that GA would be effective
against it. The stability of Shiga toxin is unknown, but we
predict it is unstable and that it will, therefore, be affected/
inhibited by PBA.
PBA and GA did not inhibit ricin. Ricin is not an ADPribosylating toxin, so we did not expect GA to have an effect.
The unfolding of ricin A chain in the ER is facilitated by an
interaction with the lipids of the inner leaflet of the ER membrane, so it may be that PBA cannot inhibit the assisted
unfolding of a toxin A chain.
Reviewing recent articles on chemical chaperones for
potential drug candidates it appears that besides PBA, other
chemical chaperones potentially useful in this invention
include glycerol, deuterated water, DMSO, and trimethylamine N-oxide (TMAO). These other reagents work in cell
culture but, due to toxicity, not so well in patients. In general,
there has been a shift to more specific "pharmacological
chaperones" which are designed to only function against the
targeted protein. PBA and the chemical chaperones are less
specific than pharmacological chaperones and can affect
many proteins. We expected that there would be non-toxic
chemical chaperones other than PBA, but after a literature
search it seems that PBA may be the only therapeutic chemical chaperone presently available.
A Therapeutic Strategy: Blocking Unfolding of Toxin A
Chain Summary
Cholera toxin (CT) moves from the cell surface to the
endoplasmic reticulum (ER) by retrograde vesicular transport. The catalytic subunit of CT (CTAl) then crosses the ER
membrane and enters the cytosol in a process that involves the
quality control mechanism of ER-associated degradation
(ERAD). The molecular details of this dislocation event are
poorly characterized. Here, we report that thermal instability
in the CTAl subunit-specifically, the loss ofCTAl tertiary
structure at 37° C.-triggers toxin dislocation. Biophysical

studies found that glycerol preferentially stabilized the tertiary structure of CTAl without having any noticeable effect
on the thermal stability of its secondary structure. The thermal disordering of CTAl tertiary structure normally preceded
the perturbation of its secondary structure, but in the presence
of 10% glycerol the temperature-induced loss of CTAl tertiary structure occurred at higher temperatures in tandem with
the loss ofCTAl secondary structure. The glycerol-induced
stabilization of CTAl tertiary structure blocked CTAl dislocation from the ER and instead promoted CTAl secretion into
the extracellular medium. This, in turn, inhibited CT intoxication. Glycerol treatment also inhibited the in vitro degradation of CTAl by the core 20S proteasome. Collectively,
these findings indicate that toxin thermal instability plays a
key role in the intoxication process and that an agent that
increases the stabilization of CTAl tertiary structure is a
potential anti-toxin therapeutic drug.
Introduction
Cholera toxin (CT) is an AB 5 protein toxin that ADPribosylates and activates the stimulatory a subunit of the
heterotrimeric G protein (Gsa). 1·2 The catalytic A moiety of
CT is synthesized as a CTA protein of 27 kDa molecular
mass. Nicking of CTA by the Vibrio cholerae hemagglutinin
protease or other proteases generates a disulfide-linked
CTA1/CTA2 heterodimer. Enzymatic activity is a property of
the 22 kDa CTAl subunit, while the 5 kDa CTA2 subunit
interacts non-covalently with the B pentamer and thereby
tethers CTAl to the CTB domain. The cell-binding B moiety
of CT is assembled from 12 kDa monomers as a homopentameric ring-like structure that adheres to GM! gangliosides
on the eukaryotic plasma membrane.
A substantial portion of surface-bound CT is delivered to
the lysosomes and degraded, but the functional pool of toxin
is instead transported to the endoplasmic reticulum (ER)
through a series of vesicular trafficking events. 3-6 The resident redox state of the ER reduces the CTA1/CTA2 disulfide
bond, which then permits chaperone-assisted dissociation of
CTAl from CTA2/CTB 5.7-9 The isolated CTAl subunit subsequently crosses the ER membrane and enters the cytosol
where it interacts with Gsa· Activated Gsa stimulates adenylate cyclase function and the production of cAMP. This leads
to the opening of chloride channels on the apical face of
intoxicated intestinal epithelial cells; the osmotic movement
of water which follows chloride efflux into the gut generates
the profuse watery diarrhea of cholera. 1·2
To move from the ER to the cytosol, CTAl uses the ERassociated degradation (ERAD) dislocation mechanism. 9-13
ERAD recognizes misfolded or misassembled proteins in the
ER and exports them to the cytosol for degradation by the 26S
proteasome. 14 CTAl export probably occurs through Sec61
and/or Derlin-1 protein-conducting channels in the ER membrane.15-17 Although CTAl is processed as an ERAD substrate, it avoids the standard ERAD route ofubiquitin-dependent proteasomal degradation because its arginine-overlysine bias limits the number of potential sites for ubiquitin
conjugation. 18 Other AB toxins such as Shiga toxin and ricin
also move from the cell surface to the ER and exploit ERAD
for entry into the cytosol. 19 ·20
Two major predictions have been derived from the ERAD
model of CTAl dislocation: (i) the C-terminal hydrophobic
region of CTAl (residues 162-192; the Al 3 subdomain) triggers ERAD-mediated toxin entry into the cytosol; and (ii) the
translocated pool of CTAl is stable in the eukaryotic cytosol. 6021 It is hypothesized that components of the ERAD
machinery interact with the CTAl 3 subdomain and subsequently unfold the toxin for passage into the cytosol. 9 CTAl
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is then thought to spontaneously refold in the cytosol, producing a stable conformation that is resistant to proteasomal
degradation. 18
We have shown that the CTAl 3 subdomain is not required
for toxin entry into the cytosol and that the translocated pool
of CTAl is not stable in the cytosol. 10 •22 Both observations
may be linked to the unstable, heat-labile nature of the CTAl
subunit. 23 •24 CTAl is held in a stable conformation when
associated with other components of the holotoxin, 24 -26 but it
can unfold spontaneously after dissociation from CTA2/
CTB 5.24 This unfolding event would activate the ERAD system and thereby promote CTAl export to the cytosol. Following dislocation into the cytosol, CTAl could retain significant
enzymatic activity because of its association with host proteins such as the ADP-ribosylation factors that serve as cofactors to enhance CTAl activity. 23 •24 •27 However, the structural state of the isolated CTAl subunit leaves it susceptible to
ubiquitin-independent degradation by the core 20S proteasome.24 With this model of toxin-ERAD interactions, an
inherent physical property of the CTAl subunit (i.e., thermal
instability) is linked to both toxin dislocation into the cytosol
and toxin degradation in the cytosol. Our model suggests
CTAl is processed as a typical misfolded/unfolded ERAD
substrate, whereas a prevailing model of toxin dislocation
treats CTAl as a stable protein that requires chaperone-assisted unfolding in order to move from the ER to the cytosol. 6·
9.16.18.28
According to our model, structural stabilization of the
CTAl subunit will inhibit CTAl dislocation and thereby prevent CT intoxication. The thermal stabilization of CTAl
should also block its degradation by the 20S proteasome,
which only acts upon unfolded substrates. 29 To test these
predictions, we examined the impact of glycerol on CTAl
structure, CTAl dislocation/degradation, and CT intoxication. Glycerol is a chemical chaperone that stabilizes protein
structures and is commonly used to disrupt ERAD-substrate
interactions. 30-34 Glycerol has also been shown, by an
unknown mechanism, to protect cultured cells against intoxication with either ricin or Shiga toxin 2. 35036 In this work we
show that glycerol prevents the temperature-induced loss of
CTAl tertiary structure, which in turn prevents CTAl dislocation into the cytosol and productive intoxication. Glycerol
also inhibited the in vitro degradation of CTAl by the 20S
proteasome. These observations provide mechanistic insight
into the molecular events underlying CTAl-ERAD interactions and suggest a new therapeutic approach for anti-toxin
countermeasures.
Results
Effect of Glycerol on CTAl Protease Sensitivity
As a first step toward evaluating the stabilizing effect of
glycerol on CTAl structure, we employed a protease sensitivity assay (FIG. 7). A final concentration of 10% glycerol
was used in order to maintain consistency with other reports
that have used this concentration of glycerol to disrupt
ERAD-substrate and/or host-toxin interactions. 31 -33 •35 •36
Protease sensitivity assays are used to probe the folding state
of a protein, as proteins often become more susceptible to
proteolysis upon (partial) unfolding. 9024037 Samples of the
reduced CTA1/CTA2 heterodimer were incubated in the
absence or presence of 10% glycerol for 45 minutes at 4° C.,
25° C., 33° C., 37° C., or41° C.All samples were then placed
on ice and exposed to thermolysin, a metalloendoprotease
that cleaves the peptide bonds in proteins at the surfaceexposed hydrophobic residues. EDTA and sample buffer
were added after 45 minutes to halt the digests, and the
samples were subsequently resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with

Coomassie staining. Since all protease treatments were performed at 4° C., differential degradation of the toxin samples
could only result from temperature-induced changes to the
structure of CTAl.
Previous work has shown that our reducing condition of 10
mM ~-mercaptoethanol (~-ME) is sufficient for complete
separation of CTAl from CTA2; 24 this result was also confirmed for CTA1/CTA2 heterodimers incubated with 10 mM
~-ME and 10% glycerol (FIG. 7(a)). Reduction of the CTAl/
CTA2 disulfide bond is necessary to examine the temperature
dependence of CTAl protease sensitivity because the covalent association of CTAl with CTA2 provides a degree of
conformational stability to CTAl which prevents its proteolysis by thermolysin. 24
The isolated CTAl subunit was largely resistant to thermolysin-mediated proteolysis when incubated at temperatures up to 33° C., but CTAl shifted to a protease-sensitive
state at 37° C. This was evidenced by a substantial weakening
of the CTAl band in the gel when the toxin was preincubated
at temperatures above 33° C. before thermolysin treatment
(FIG. 7(b)). Little change in CTAl band intensities were
observed in the temperature range of 4° C. to 41° C. for toxin
samples treated with 10% glycerol, indicating that treatment
with 10% glycerol prevented the transition of CTAl to a
protease-sensitive state at 3 7° C. and 41 ° C. In contrast, under
identical buffer conditions glycerol treatment did not prevent
the thermolysin-mediated proteolysis of a-casein, a protein
with an open and flexible conformation38 (data not shown).
The inhibitory effect of glycerol on CTAl proteolysis was
thus unlikely to result from a direct inhibition of thermolysin
activity. Instead, glycerol treatment appeared to keep CTAl in
a folded, protease-resistant conformation at 37° C. and 41° C.
Effect of Glycerol on CTAl Thermal Stability
Biophysical experiments were performed in order to
directly examine the impact of glycerol on CTAl thermal
instability (FIG. 8). Near- and far-UV circular dichroism
(CD) measurements were conducted on Hisetagged CTAl in
the absence or presence of 10% glycerol. Readings were
taken during a step-wise increase in temperature from 18° C.
to 65° C. Near-UV CD measurements detected the disordering ofCTAl tertiary structure (FIGS. 8(a) and 8(c)), while
far-UV CD measurements detected the unfolding of CTAl
secondary structure (FIGS. 8(b) and 8(d)). To avoid errors
from sample-to-sample variability, both measurements were
conducted near-simultaneously on the same sample. The data
from these experiments were used to generate CTAl thermal
unfolding profiles (FIGS. 8(e) and 8(1)) which were, in turn,
used to calculate the amount of initial (18° C.) tertiary and
secondary structure remaining in CTAl at various temperatures (Table 1, below). The tertiary structure of CTAl exhibited a transition temperature (Tm) of34± 1° C. in the untreated
control condition and a Tm of 39.5±1° C. in the presence of
glycerol (Table 2). Untreated CTAl only retained 33% of its
initial tertiary structure at 37° C., whereas glycerol-treated
CTAl retained 58% of its initial tertiary structure at 37° C. In
contrast, the thermal unfolding profile of CTAl secondary
structure was not shifted by glycerol: in both the absence and
presence of 10% glycerol, CTAl exhibited a secondary structure Tm of39±0.5° C. and retained-60% of its initial secondary structure at 37° C. These data delineate a significant effect
of glycerol on the heat-sensitivity of CTAl tertiary structure.
The thermal disordering of CTAl tertiary structure normally
preceded the perturbation ofCTAl secondary structure, 24 but
in the presence of 10% glycerol the temperature-induced loss
of CTAl tertiary structure was shifted to higher temperatures
and occurred in parallel with the loss of CTAl secondary
structure. Thus, glycerol treatment preferentially increased
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the thermal stability of the tertiary structure of CTAl while
exerting little effect on the secondary structure of the protein.
Effect of Glycerol on CTAl Dislocation
According to our model, the thermal stabilization ofCTAl
should block its export to the cytosol. A previously described
assay 28 for monitoring CTAl dislocation from the ER was
used to test this prediction (FIG. 9(a)). HeLa cells incubated
on ice for 30 minutes with 1 mg/ml of CT were chased for 2
hours at 37° C. in toxin-free medium that lacked or contained
10% glycerol. Previous studies have demonstrated that glycerol equilibrates across the plasma membrane with a t 112 of 5
minutes, 32 while it takes about 45 minutes for a fraction of
surface-bound CT to reach the ER. 5 •16 Selective permeabilization of the plasma membrane with digitonin was used to
partition the toxin-treated cells into two fractions that contained either (i) the plasma membrane and intact intracellular
membranes or (ii) the cytosol. Control experiments demonstrated that protein disulfide isomerase (PDI), a soluble ER
protein, was only found in the pellet fractions (i.e., ER and
other membranes) of untreated and glycerol-treated cells.
Furthermore, the cytosolic protein Hsp90 was found in the
supernatant fractions (i.e., cytosol) of both untreated and
glycerol-treated cells. Our fractionation procedure could thus
clearly separate cell extracts into distinct organelle and cytosolic components. CTAl was only detected in the pellet fracti on after pulse labeling at 4 ° C., a temperature that blocks the
endocytosis of surface-bound protein. However, as expected,
a portion of surface-bound CTAl entered the cytosolic fraction after a 2 hour chase at 3 7° C. Less CTAl was found in the
cytosol of glycerol-treated cells than in the cytosol of
untreated control cells (FIG. 9(a)). Semi-quantitative analysis of our dislocation assay indicated that 23±8% of the total
cellular pool of CTAl was present in the cytosolic fraction of
untreated cells, and 7±4% of the total cellular pool ofCTAl
was present in the cytosolic fraction of glycerol-treated cells
(n=2). In the two individual experiments, glycerol treatment
resulted in a 3-fold or 5-fold reduction in cytosolic CTAl.
This indicated that the glycerol-induced stabilization of
CTAl tertiary structure inhibited CTAl dislocation into the
cytosol.
Surface plasmon resonance (SPR) was used as an alternative method to detect the cytosolic pool of CTAl (FIG. 9(b )).
Cytosolic fractions from intoxicated HeLa cells were prepared as described above and perfused over an SPR sensor
slide that was coated with an anti-CTA antibody. No signal
was obtained from the cytosol of unintoxicated HeLa cells
and from the cytosol of intoxicated cells treated with brefeldin A (BfA), a drug that blocks toxin trafficking to the ER
dislocation site. 5 •39 Cells intoxicated in the presence of 10%
glycerol also failed to generate a positive cytosolic signal for
CTAl (n=4). In contrast, we could reproducibly detect the
cytosolic pool of CTAl from intoxicated but otherwise
untreated control cells. When this assay was repeated as a five
hour time course experiment, we recorded a time-dependent
increase in the cytosolic pool ofCTAl. However, CTAl could
not be detected in the cytosol of glycerol-treated cells at 1, 2,
3, 4, or 5 hours of chase (FIG. 15). The apparent discrepancy
between this result and the result presented for Western blot
analysis of toxin dislocation, in which a minor pool of CTAl
was detected in the cytosol of glycerol-treated cells (FIG.
9(a)), stems from a procedural difference in the detection
methods. For SPR analysis, the cytosolic fractions had to be
diluted in order to obtain a sufficient volume of sample to run
through the SPR instrument. This process apparently diluted
the cytosolic pool of CTAl from glycerol-treated cells to a
level below the threshold of detection for SPR. However, both
SPR and Western blot analysis recorded the same qualitative

effect: less CTAl was found in the cytosol of glycerol-treated
cells than in the cytosol of untreated control cells. These
collective observations provided additional support for our
conclusion that the glycerol-induced thermal stabilization of
CTAl prevented toxin dislocation to the cytosol.
Effect of Glycerol on CTAl Secretion from Intoxicated Cells
Misfolded or misassembled proteins and proteins with specific targeting determinants are effectively retained in the ER;
all other proteins are packaged into vesicle carriers for transport to the Golgi apparatus and beyond. 14 Stabilization of the
CTAl tertiary structure could therefore generate a folded
toxin conformation that is recognized as secretory cargo and
accordingly directed to vesicle traffic in the biosynthetic
secretory pathway. In this case, glycerol treatment would
result in the secretion of CTAl from intoxicated cells. To
examine this possibility, SPR was used to detect CTAl in the
extracellular medium of cells intoxicated in the absence or
presence of 10% glycerol (FIG. 10). A minimal background
signal was detected when the medium from unintoxicated
HeLa control cells was perfused over a SPR sensor slide that
had been coated with an anti-CTA antibody. A positive signal
was detected when the medium from intoxicated cells was
perfused over the sensor slide, and an even stronger signal
was obtained from the medium of intoxicated cells incubated
with 10% glycerol (FIG. 10). This indicated that, as previously reported, some amount of CTAl was released into the
medium during the normal intoxication process. 3 However, a
greater amount of CTAl was released into the medium when
the toxin was stabilized by glycerol treatment (FIG. 10). No
signal was detected when the experiment was performed with
a sensor slide that had been coated with an anti-CTB antibody, thus demonstrating that the positive response from the
CTA sensor slide did not result from the presence of CT
holotoxin in the medium (data not shown). Similar results
were obtained with Vero cells which, unlike HeLa cells, did
not require GM! pre-treatment before intoxication (FIG. 16).
Thus, the results of the HeLa secretion assay could not be
attributed to GM! treatment or to cell-type specific effects.
Because CTAl dissociates from CTA2/CTB5 in the
ER,7-9 the secretion of CTAl from glycerol-treated cells
strongly suggested that 10% glycerol did not inhibit trafficking of the CT holotoxin to the ER. BfA, a drug that disrupts
toxin transport to the ER, 5 •39 was used to strengthen this
interpretation. When the SPR secretion assay was repeated
with cells exposed to BfA, we could not detect an appreciable
amount ofCTAl in the medium ofintoxicated cells incubated
in either the absence or presence of 10% glycerol (FIGS.
ll(a) and b)). Thus, toxin trafficking to the ER was a prerequisite for CTAl secretion. The kinetics of secretion also indicated that intracellular toxin trafficking preceded the release
ofCTAl into the medium: substantial amounts of extracellular CTAl were not detected until 90 minutes into the chase
period, after which a greater amount of CTAl was released
into the medium (FIGS. ll(a) and (b)). Analysis of these
kinetic data and the data presented in FIG. 10 indicated that
glycerol-treated cells secreted twice as much CTAl as the
untreated control cells (FIG. ll(c)). Given that only a minor
fraction (-5%) of cell-associated CT reaches the ER, 5 •39 a
two-fold increase in CTAl secretion from glycerol-treated
cells may represent the bulk of ER-localized toxin. It thus
appeared that the glycerol-stabilized pool of CTAl was
treated as secretory cargo rather than as an ERAD substrate
and was accordingly released into the extracellular medium.
Effect of Glycerol on CTAl Dissociation from the Holotoxin
Results from the SPR secretion assays indicated that glycerol treatment did not prevent CTAl dissociation from the
holotoxin: if glycerol inhibited this event, CTAl would be

5

10

15

20

25

30

35

40

45

50

55

60

65

US 8,436,048 Bl
17

18

tethered to CTA2/CTB 5 and could not enter the extracellular
medium in a soluble state. An SPR-based experiment directly
confirmed that glycerol treatment did not prevent CTAl dissociation from theholotoxin (FIG.12). In this experiment, the
CT holotoxin was appended to a GMl-coated sensor slide.
Reduced PDI was then perfused over the sensor slide in the
presence of 10% glycerol. Previous biochemical work has
shown that reduced PDI facilitates the dissociation of CTAl
from CTA2/CTB 5 . 9 Our SPR experiment confirmed this PD!mediated event also occurs in the presence of 10% glycerol.
Reduced PDI bound to CT and accordingly generated an
increase in the measured refractive index. Although PDI was
present in the perfusion buffer throughout the experiment, the
refractive index began to drop precipitously 290 seconds into
the experiments and eventually fell below the initial baseline
value which represented the mass of the CT holotoxin. It thus
appeared that both PDI and a component of the CT holotoxin
were removed from the sensor slide. This would occur if PDI
facilitated the dissociation of CTAl from CTA2/CTB 5 : since
the B pentamer was bound to the sensor slide, the release of
CTAl from the holotoxin would wash both PDI and CTAl off
the plate. To confirm that CTAl was removed from the sensorbound toxin, we perfused an anti-CTA antibody over the
sensor slide. No signal was obtained with the anti-CTA antibody, thus indicating that CTAl was absent from the PDItreated toxin. In contrast, the anti-CTA antibody generated a
robust signal when perfused over a sensor slide containing the
intact CT holotoxin (data not shown). 24 Additional control
experiments with anti-CTB, anti-KD EL, or anti-PDI antibodies demonstrated that CTB and the KDEL-tagged CTA2 subunit, but not PDI, remained on the SPR sensor slide after the
loss ofCTAl (data not shown).
Effect of Glycerol on CT Intoxication
The glycerol-induced block of CTAl dislocation into the
cytosol should prevent productive CT intoxication. To test
this prediction, we monitored cAMP levels in untreated and
glycerol-treated cells that had been continually exposed to
varying concentrations of CT for 2 hours (FIG. 13).
Glycerol-treated cells were indeed resistant to CT.
Whereas a 50% maximal response was obtained with 3 ng of
CT/ml in the untreated control cells, 35 ng of CT/ml was
required to elicit the same effect in glycerol-treated cells. This
effect was most likely due to direct inhibition of the CT
intoxication process, as control experiments found that glycerol did not inhibit forskolin-stimulated adenylate cyclase
activity: cells treated with glycerol and forskolin produced
105% of the cAMP signal generated by cells treated with
forskolin alone. Furthermore, our SPR experiments demonstrated that glycerol treatment did not prevent CT trafficking
to the ER or CTAl dissociation from the holotoxin. Thus, the
glycerol-induced inhibition of CT intoxication most likely
resulted from the glycerol-induced block of CTAl dislocation to the cytosol.
Effect of Glycerol on CTAl Degradation by the 20S Proteasome
CTAl is an in vitro substrate for ubiquitin-independent
degradation by the 20S proteasome. 24 This macromolecular
complex forms the catalytic core of the 26S proteasome,
which is generated by the addition of a l 9S cap to one or both
ends of the barrel-shaped 20S proteasome. The function of
the l 9S regulatory domain is ubiquitin recognition and ATPdependent substrate unfolding, so the core 20S proteasome
can only degrade a limited number of unfolded proteins in a
ubiquitin- and ATP-independent process. 29 To determine
whether the stabilization of CTAl tertiary structure inhibited
toxin degradation by the 20S proteasome, we incubated a
reduced CTA1/CTA2 heterodimer with the purified 20S pro-

teasome for up to 20 hours in the absence or presence ofl 0%
glycerol (FIG. 14(a)). Degradation of the reduced, isolated
CTAl subunit by the 20S proteasome was detected after 3
hours of co-incubation in our control condition and was
nearly complete by 20 hours of co-incubation. However, substantial inhibition of CTAl degradation by the 20S proteasome was observed when the toxin was incubated with both
10% glycerol and the 20S proteasome. Glycerol did not
inhibit a-casein degradation by the 20S proteasome (FIG.
14(b)), which demonstrated that 10% glycerol did not directly
impair the in vitro activity of the core 20S proteasome. The
stabilization of CTAl tertiary structure by glycerol thus prevented its ubiquitin-independent degradation by the 20S proteasome.
Discussion
Toxin-ERAD interactions were originally thought to
involve the C-terminal hydrophobic region of CTAl, but
recent work has shown that this domain is not required for
CTAl dislocation. 22 An alternative ERAD trigger could
derive from the unstable, heat-labile nature of the isolated
CTAl polypeptide. 23 •24 With this model, the global loss of
CTAl structure that accompanies its dissociation from the
holotoxin would identify it as a misfolded protein for ERAD
processing. We accordingly predicted that the thermal stabilization of CTAl would prevent its export to the cytosol and,
hence, productive intoxication. The results of our experiments with glycerol-treated cells, combined with biophysical
studies on purified proteins, support this prediction. Our findings identify the thermal unfolding ofCTAl tertiary structure
as a requirement for ERAD recognition and thus provide a
novel molecular mechanism for ERAD-mediated CTAl dislocation.
The thermal disordering of CTAl tertiary structure normally preceded the thermal denaturation of CTA 1 secondary
structure by 5-6° C. 24 However, here we show that in the
presence of 10% glycerol the loss of CTAl tertiary structure
was shifted to higher temperatures and occurred concomitantly with the loss ofCTAl secondary structure. Glycerol did
not affect the thermal perturbation of CTAl secondary structure, so the glycerol-induced effects on toxin processing
apparently resulted from the specific stabilization of CTAl
tertiary structure.
The near-UV CD signal around 280 nm that was used to
track changes in CTAl tertiary structure involves contributions from both Trp and Tyr residues. Two of the three CTAl
Trp residues that make substantial contributions to the nearUV CD signal are present in the C-terminal domain that has
previously been shown to be in a partially unfolded state. The
glycerol-induced stabilization ofCTAl tertiary structure may
therefore involve an effect on the C-terminal Al 3 subdomain.
In this scenario, unfolding of the CTAl C-terminus would
precede the loss of additional structure in the remainder of the
toxin. Since the Al 3 subdomain is not necessary for CTAl
dislocation, the temperature-induced loss of structure in other
regions of CTAl would serve as the ERAD trigger. This
possibility is consistent with our interpretation of the available data-namely, that the thermal unfolding of CTAl tertiary structure is required to activate the ERAD system. Additional structural studies will delineate the process of CTAl
thermal unfolding which begins with the loss of tertiary structure. Here, we focused on the disruption of host-toxin interactions resulting from the glycerol-induced stabilization of
CTAl tertiary structure.
Control conditions ensured that the glycerol-induced
effects were due to the impact of glycerol on CTAl structure
rather than to the action of glycerol on other components of
the experiment. For example, we used a-casein, a protein with
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a flexible and open structure, 38 to demonstrate that glycerol
did not directly inhibit the proteolytic activities of thermolysin or the 20S proteasome. Additional experiments demonstrated that glycerol treatment did not disrupt (i) holotoxin
trafficking to the ER; (ii) chaperone-assisted dissociation of
CTAl from CTA2/CTB 5 ; (iii) secretion of the dissociated
CTAl subunit; or (iv) cAMP production from activated adenylate cyclase. Other studies have further shown that glycerol
treatment does not affect the vesicular transport of secretory
cargo, N-linked glycosylation in the endomembrane system,
the functioning of chloride charmels, or the ERAD-independent ER dislocation of the A subunit from Haemophilus
ducreyi cytolethal distending toxin. 32 - 34 •40 Thus, the impact
of glycerol on CTAl processing is highly unlikely to result
from generic cellular effects. It instead appears to have
resulted specifically from the stabilization of CTAl tertiary
structure.
There is one established case in which glycerol treatment
does have a general effect on cellular events: chemical chaperones such as glycerol stabilize the folding intermediates in
protein biogenesis, and this has been shown to alter the processing of many ERAD substrates. 30 - 34 CTAl therefore acts
as a typical misfolded/unfolded ERAD substrate, which contradicts a prevailing model oftoxin-ERAD interactions that
treats CTAl as a stable protein. 6·9 •18 •18 •28
Glycerol treatment did not prevent CT trafficking to the ER
or CTAl dissociation from the holotoxin. However, glycerol
treatment did prevent the ER-to-cytosol dislocation ofCTAl.
CT intoxication was consequently impaired in glyceroltreated cells. These effects, which specifically resulted from
the stabilization of CTAl tertiary structure, demonstrated the
functional consequences of CTAl thermal stabilization. The
trigger for ERAD-mediated dislocation thus appears to derive
from a global loss of CTAl tertiary structure rather than from
the presence of a specific domain or motif within the toxin. As
such, CTAl does not masquerade as misfolded protein to
activate the ERAD system. CTAl is instead recognized as an
ERAD substrate because, upon holotoxin disassembly, the
thermal disordering of its tertiary structure produces an
unfolded toxin conformation.
The thermal stabilization of CTAl blocked its ERADmediated dislocation to the cytosol and instead promoted its
secretion into the extracellular medium. This suggested that
the stabilized pool of CTAl was not retained in the ER of
glycerol-treated cells but was instead treated as normal secretory cargo and released into the medium. A relatively small
portion of cell-associated CT (-5%) reaches the ER, 5 •39 so the
two-fold increase in CTAl secretion from glycerol-treated
cells may represent the bulk of ER-localized toxin. Since the
secreted pool of CTAl was not linked to its cell-binding B
subunit, it could not reassociate with target cells and was
therefore functionally inactive. The release of CTAl from
glycerol-treated cells would also prevent its accumulation in
the ER and any resulting ER stress response. Given these
considerations, it appears thatA chain thermal stabilization is
a promising anti-toxin therapeutic strategy.
CTAl is degraded in vivo by a relatively slow, ubiquitinindependent proteasomal mechanism. This process likely
involves the core 20S proteasome, which can degrade CTAl
in an ATP- and ubiquitin-independent marmer in vitro. 24 The
glycerol-induced inhibition ofCTAl degradation by the 20S
proteasome indicated that the loss of toxin tertiary structure is
responsible for targeting CTAl to the 20S proteasome. This
interpretation is consistent with a previous report that concluded the 20S proteasome recognizes substrates with disordered tertiary structures. 41 Collectively, these data suggest
that CTAl degradation in the host cell cytosol results from the

thermal disordering ofCTAl tertiary structure. The slow rate
ofCTAl turnover in vivo, which under normal circumstances
does not impact intoxication, 18 most likely reflects inefficient
processing by the 20S variant of the proteasome and/or CTAl
association with stabilizing host proteins such as the ADPribosylation factors. 23 "24
Our collective data indicate that CTAl thermal instability
plays an essential role in the intoxication process. Thus, the
thermal stabilization ofCTAl is a novel target for anti-toxin
therapeutics. We have provided proof-of-principle for this
concept by demonstrating that the glycerol-induced stabilization of CTAl tertiary structure blocks toxin dislocation
from the ER and productive intoxication. Exposure to high
concentrations of glycerol is not a viable therapeutic option,
but other chemical chaperones or target-specific "pharmacological chaperones" can stabilize protein conformations without toxic side-effects. 42 Other ER-dislocating toxins also
contain thermally unstable A chains, 37043044 so the use of
chemical or pharmacological chaperones for toxin thermal
stabilization may represent a new, general strategy for antitoxin treatments.
Materials and Methods
Chemicals, thermolysin, a-casein, rabbit anti-CTA antibody, and ganglioside GM! were purchased from SigmaAldrich (St. Louis, Mo.). CT was purchased from List Biological Laboratories (Campbell, Calif.). Cell culture reagents
were purchased from Invitrogen (Carlsbad, Calif.). ATP and
the purified CTA1/CTA2 heterodimer were purchased from
Calbiochem (La Jolla, Calif.). The purified 20S proteasome
was from Boston Biochem (Cambridge, Mass.). [35 S]methionine was purchased from Perkin-Elmer (Boston, Mass.).
Rabbit anti-Hsp90 and anti-PDI antibodies were purchased
from Stress gen Bioreagents Corp. (Victoria, BC Canada); the
horseradish peroxidase-conjugated goat anti-rabbit IgG antibody was from Jackson Immunoresearch Laboratories Inc.
(West Grove Pa.); and Talon beads were from Clontech Laboratories (Mountain View, Calif.).
Protease Sensitivity Assay
A master mix containing 6 mg of CTA1/CTA2, 10 mM
6-ME, and 20 mM sodium phosphate (pH 7 .0) was prepared
in a volume of 120 ml. A second master mix was prepared as
above but with a final concentration of 10% glycerol. The
mixes were divided into 20 ml aliquots and incubated at 4° C.,
25° C., 33° C., 37° C., or 41° C. for 45 minutes. The aliquots
were then placed on ice for 10 minutes, after which 2 ml of
thermolysin was added to all the samples for a 1 hour incubation at 4 ° C. Thermolysin, prepared as a 1Oxstock in 50 mM
CaC1 2 and 100 mM Hepes (pH 8.0), was added to a final
concentration of 0.04 mg/ml. Digestions were halted by the
addition of ethylenediaminetetraacetic acid (EDTA) to a final
concentration of 10 mM. Samples were analyzed by SDSPAGE with 15% polyacrylamide gels. Coomassie staining
was used to visualize the samples.
CTA1-His6 Purification
Escherichia coli strain BL21 pLysS was transformed with
an inducible CTA1-His 6 expression plasmid22 and grown at
37° C. in I liter Luria-Bertani broth to anA 600 of0.6. CTA1His6 expression was induced by addition of 1 mM IPTG to the
growth medium. The cells were pelleted after 4 hrs of induction, resuspended in extraction buffer (20 mM Tris-HCl, pH
7.0, 300 mM NaCl, 0.1% Triton X-100, 1% deoxycholate,
100 mg/ml of lysozyme, and 8 M urea), and lysed with three
freeze-thaw cycles. The insoluble lysate fraction was
removed with a 30 min, 12,000xg spin. The soluble fraction
was then supplemented with a protease inhibitor cocktail and
incubated in batch with Talon resin for 30 min at room temperature. Unbound material in the supernatant was removed
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with a 5 min spin at 700xg, and the resin was washed four
times with extraction buffer containing 600 mM NaCl. To
elute the bound toxin, the resin was placed in a column and
exposed to increasing concentrations of imidazole in extraction buffer(lO, 15, 20, 25, 35, 40, 45, and lOOmMimidazole;
2 mis for each concentration). Fractions of 0.5 ml volume
were collected and analyzed by SDS-PAGE. Before experimental use, the fractions containing purified CTA1-His 6 were
dialyzed against five changes of 500 ml sodium phosphate
buffer (pH 7.4) in order to facilitate the refolding ofCTAl: the
first step was for 2 hr at room temperature in 6 M urea buffer;
the second step was overnight at 4 ° C. in 4 M urea buffer; the
third step was for 2 hrs at 4 ° C. in 2 M urea buffer; the fourth
step was for 1 hr at 4 ° C. in urea-free buffer; and the last step
was for 20 min at 4° C. in urea-free buffer. Slide-a-lyzer 3500
MWCO dialysis cups (Pierce, Rockford, Ill.) were used for
the procedure. After dialysis, CTA1-His 6 was used immediately for experimentation.
CD Measurements
A J-810 spectrofluoropolarimeter (Jasco Corp., Tokyo,
Japan) with a Jasco PFD-425S Peltier temperature controller
was used to study the temperature-dependent unfolding of
CTA1-His 6 . Near- and far-UV CD measurements were performed with a 4-mm optical path-length rectangular quartz
cuvette at a protein concentration of 73 mg/ml in 20 mM
sodium borate buffer (pH 7.4) containing 150 mM NaCl.
Thermal unfolding was carried out in the temperature range
of 18-65° C. Samples were equilibrated for 4 minutes at each
temperature, followed by measurements of CD spectra from
195 to 325 nm. Five scans were recorded and averaged per
spectrum. The observed ellipticity was converted to mean
residue molar ellipticity, [8], in units of degreesxcm2 xdmo1- 1
using [8]=8 06 )cnre), where 8 obs is the measured ellipticity in
millidegrees, c is the molar concentration of the protein, nres
is the numberofamino acid residues in the protein, and I is the
optical path-length in millimeters. The temperature-dependent protein unfolding data were analyzed as previously
described. 24 The thermal unfolding profiles for TA1-His 6
were nearly identical to the profiles reported for native CTAl,
which in the reduced state exhibited a secondary structure Tm
of37.5° C. and a tertiary structure Tm of32° C. 24
The change in the near-UV CD signal at 280 nm reflects
two things: the local environment ofTrp and Tyr residues, and
the conformation of the side chains of these residues.
Changes in the local environment are caused by changes in
the protein tertiary structure. A more tightly packed tertiary
structure brings the main chain Ca atoms closer to the aromatic side chains and makes their local environment more
chiral, thus affecting the aromatic side chain CD signal. As
such, the changes in the near-UV CD signal around 280 nm
reflect (i) changes in the local environment of Trp and Tyr
residues and, thus, the protein tertiary structure; and (ii) the
conformations of Trp and Tyr side chains. We accordingly
interpreted the changes in this signal in terms of protein
tertiary structure.
Dislocation and Secretion Assays
HeLa cells were seeded into 6 well plates and grown overnight to a density of approximately 10,000 cells/well. Duplicate wells were used for each condition. To begin the experiment, the cells were incubated for 1 hour at 37° C. in serumfree medium containing 100 ng/ml of ganglioside GM!. This
medium was subsequently replaced with serum-free medium
containing 1 mg/ml of CT. After a 30 minute incubation at 4°
C., the cells were washed twice with phosphate buffered
saline (PBS) and placed in toxin/serum-free medium that
either lacked or contained 10% glycerol. The cells were then
incubated for 2 hours at 3 7° C. Media samples were collected

for analysis by SPR, and cells were lifted from the plate using
750 ml of0.5 mM EDTA in PBS. Both wells for each condition were added to a single microcentrifuge tube which was
spun at 5,000xg for 5 minutes at room temperature. The
supernatant was discarded, and the cell pellet was resuspended in 100 ml of0.04% digitonin in HCN buffer (50 mM
HEPES, pH 7.5, 150mMNaCI, 2 mMCaCl 2 , lOmMN-ethylmaleimide, and a protease inhibitor cocktail) for a 10
minute incubation at 4° C. The digitonin-treated cells were
spun at 16,000xg for 10 minutes at room temperature, after
which the supernatant (i.e., cytosolic fraction) was collected
and placed in a fresh microcentrifuge tube. For experiments
involving Western blot analysis, 120 ml of lx sample buffer
was added to the pellet and 20 ml of 4x sample buffer was
added to the supernatant.
Western Blot
25 ml samples resolved by SDS-PAGE with 15% polyacrylamide gels were subsequently transferred to a PVDF membrane. The membrane was incubated overnight at 4 ° C. with
primary antibody (rabbit anti-Hsp90 at 1:20,000 dilution;
rabbit anti-PDI at 1:5,000 dilution; or rabbit anti-CTA at
1:20,000 dilution). The membrane was then incubated at
room temperature for 30 minutes with a secondary antibody
(horseradish peroxidase-conjugated goat anti-rabbit IgG at
1:20,000 dilution). ECL Plus Western blotting detection
reagents (GE Healthcare) were used for protein detection
according to the manufacturer's instructions. Separate blots
were run for each protein.
For semi-quantitative analysis of our dislocation assay, the
amount of cytosolic CTAl was calculated with the following
equation: % cytosolic CTAl =CTAl supernatant signal/
[CTAl supernatant signal+CTAl pellet signal]. This calculation provides an internal control, as the amount of cytosolic
CTAl is expressed as a ratio of total cell-associated CTAl for
each experimental condition. Thus, there is no direct comparison of band intensities between separate cell extracts
representing control and experimental conditions (i.e.,
+/-glycerol treatment).
SPR Analysis
Experiments were performed with a Reichert (Depew,
N.Y.) SR7000 SPR Refractometer. To generate sensor slides
coated with an anti-CTA antibody, an EDC-NHS activation
buffer was perfused over a Reichert gold-plated glass slide for
10 min at a flow rate of 5 ml/min. The same flow rate was used
for all steps of the procedure. A 5 min wash with PBS (pH 7.4)
containing 1% TritonX-100 (PBST) was used to remove the
activation buffer, after which an anti-CTA antibody at 1:2000
dilution in PBST was perfused over the slide for 15 min.
Unbound antibody was removed with a 5 min PBST wash,
and the remaining active groups on the sensor slide were
deactivated with a 3 min exposure to ethanolamine.
To detect the cytosolic or secreted pools of CTAl, PBST
(pH 7.4) was perfused over the CTA sensor slide for 5 min to
establish a baseline reading. Experimental samples were then
flowed over the sensor slide. Before use, cytosolic fractions
from the dislocation assay were diluted in HCN buffer to a
final volume of 1 ml. This step was necessary in order to
obtain a sufficient volume of sample to run through the SPR
instrument. For the secretion assay, all media samples were
standardized to a final concentration of 5% glycerol (2 ml
final volume) in order to eliminate any differential effect
glycerol might have on detection by the SPR instrument. CTA
standards diluted in HCN buffer or 5% glycerol were used for
the dislocation assay and secretion assay, respectively. Identi cal results were obtained for CTA standards diluted in either
HCN buffer or HCN buffer containing cellular extracts generated from unintoxicated cells (data not shown); this dem-
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onstrated that the data obtained from our dislocation assay
were not affected by the presence of cytosol. Experimental
samples were removed from the perfusion buffer after exposure to the SPR sensor for approximately 180 sec. This process usually results in a loss of signal which reflects the
dissociation rate constant. However, for these experiments,
the strong antibody-antigen interaction prevented any significant loss of signal due to ligand dissociation. After each
reading, bound ligand was stripped from the sensor slide with
a 5 min PBSTwash at pH 6.0. The Reichert Labview software
was used for data collection.
Preliminary experiments found that the pellet fractions
from our dislocation assay produced SPR signals that were
off-scale in relation to the weaker signals from the cytosolic
fractions. We therefore focused on the relative signal intensities of the cytosolic fractions. The disparity between
organelle and cytosol signals for CTAl was consistent with
the small fraction of cell-associated CTAl ( -5%) that reaches
the ER and, subsequently, the cytosol. 5 •39 An additional control experiment demonstrated that the cytosolic fractions did
not contain a factor that inhibited the detection of CTAl:
nearly identical SPR signals were obtained from 10 ng/ml of
CTA in buffer and from 10 ng/ml of CTA that had been added
to a cytosolic fraction obtained from unintoxicated HeLa
cells.
The association rate constant derived from SPR data is
directly proportional to ligand concentration. 45 Thus, to
determine the amount of CTAl secreted from intoxicated
cells, association rate constants were calculated for the SPR
data obtained from the experimental samples of FIG. 4, from
the 120 min experimental samples from FIGS. S(a) and S(b),
and from the ten-fold serial dilutions of purified CTA that
were perfused over the sensor slide as controls for FIGS. 4
and 5. The BioLogic (Campbell, Australia) Scrubber 2 software was used to derive the association rate constants from
our SPR data. The association rate constants for the CTA
standards were plotted as a function of protein concentration.
The slope of the resulting standard curve was then used to
calculate the concentrations of CTAl in untreated and glycerol-treated media samples.
For SPR experiments using PDI and the CT holotoxin, a
gold plate sensor was coated with the GM! ganglioside receptor of CT by a procedure described for the coating of ELISA
plates. 46 CT was then bound to the GMl-coated sensor by
perfusing 1 ml of CT (10 mg/ml) over the slide for 15 min at
a flow rate of5 ml/min. The CT sensor was equilibrated at 37°
C. in PBST and 10% glycerol for 10 min at a flow rate of 45
ml/min. The SPR instrument was then calibrated with a baseline measurement corresponding to the mass of the bound CT
holotoxin. PDI was subsequently perfused over the sensor at
a flow rate of 45 ml/min. PDI was diluted to a final concentration of 100 mM in PBST containing 10% glycerol and 1
mM GSH. After 420 seconds, the PDI injection was replaced
with an identical PDI buffer that also contained 80 mM of an
anti-CTA antibody. This PDI/antibody mixture was perfused
over the sensor slide at a flow rate of 45 ml/min for 420
seconds. Control experiments demonstrated that holotoxin
disassembly did not occur upon exposure to either 1 mM GSH
alone or to PDI in the absence of GSH.
Toxicity Assay
CHO cells were seeded into 24 well plates and grown
overnight to 80% confluency. The medium was removed and
replaced with serum-free medium containing the stated concentrations of CT in the absence or presence of 10% glycerol.
After a 2 hour incubation, the cells were washed with PBS and
exposed to 0.25 mL of ice-cold acidic ethanol (1 M HCI:
100% EtOH at a 1: 100 ratio) for 15 minutes at 4 ° C. The cell

extracts were then transferred to microcentrifuge tubes and
allowed to air dry at room temperature. cAMP levels were
determined using an [1 25 I]cAMP competition assay as per
manufacturer's instructions (Amersham Biosciences). The
basal levels of cAMP determined from unintoxicated cells
were background-subtracted from the values obtained for
toxin-treated cells; the maximal response from all conditions
was arbitrarily set to 100%; and all other results were
expressed as ratios of that 100% value. All conditions were
performed in triplicate.
20S Proteasome Assay
A 100 ml master mix was prepared with 1 µg 20S proteasome, 5 µg substrate, 3 mM ATP, 10 mM ~-ME, 10 mM
MgCl 2 , 100 mM KC!, 0.1 mM CaCl 2 , and 50 mM Hepes (pH
7 .5). A second master mix was prepared as above but with a
final concentration of 10% glycerol. The mixtures were
placed at 37° C., and 20 ml aliquots were removed at 0, 4, 8,
and 20 hours of incubation. Samples were analyzed by SDSPAGE with Coomassie staining.
Hsp90 is Required for Transfer of the Cholera Toxin Al
Subunit from the Endoplasmic Reticulum to the Cytosol
Cholera toxin (CT) is an ABS toxin that moves from the
cell surface to the endoplasmic reticulum (ER) by retrograde
vesicular transport. In the ER, the catalytic Al subunit dissociates from the rest of the toxin and enters the cytosol by
exploiting the quality control system of ER-associated degradation (ERAD). The driving force for CTAl dislocation
into the cytosol is unknown. Here, we demonstrate that the
cytosolic chaperone Hsp90 is required for CTAl passage into
the cytosol. Hsp90 bound to CTAl in an ATP-dependent
manner that was blocked by geldanamycin (GA), an established Hsp90 inhibitor. CT activity against cultured cells was
also blocked by GA, as was the ER-to-cytosol export of
CTAl. Experiments using N-ethylcarboxamidoadenosine
(NECA), a drug that inhibits ER-localized GRP94 but not
cytosolic Hsp90, confirmed that the inhibitory effects of GA
resulted specifically from the loss of Hsp90 activity. GRP94
is glucose-regulated protein of 94 kDa, a major luminal constituent of the endoplasmic reticulum and paralog of Hsp90;
by amino acid homology, Grp94 is about 60% homologous
and 50% identical to Hsp90a. This work establishes a functional role for Hsp90 in the ERAD-mediated dislocation of
CTAl.
ERAD substrates are extracted from the ER through a
mechanism that often involves the AAA ATPase Cdc48/p97.
However, p97 appears to play a minimal role in CTAl dislocation. An alternative model has proposed a ratchet mechanism which involves the spontaneous refolding of CTAl as it
enters the cytosol. Recent CTAl structural studies do not
support this model, as it has been shown that the isolated
CTAl subunit is a disordered, thermally unstable protein.
Since CTAl is in a partially unfolded conformation at 37° C.,
an as yet unidentified host protein must provide the driving
force for CTAl extraction from the ER.
Hsp90 functions in toxin translocation across the endosomal membrane, but its potential role in ERAD-mediated toxin
dislocation has not been examined. To address this issue,
surface plasmon resonance (SPR) was used to determine
whether Hsp90 could directly interact with the isolated CTAl
subunit. Hsp90 binding to CTAl occurred in an ATP-dependent marmer that was blocked by GA (FIG. 17A). The interaction between CTAl and Hsp90-ATP was not affected by
NECA, a drug that inhibits GRP94 but not Hsp90 (FIG. 17A).
GRP94, an ER-localized Hsp90, also bound to CTAl in an
ATP-dependent process that was blocked by both GA and
NECA (FIG.17B). The interaction between Hsp90 andCTAl
was much stronger than the interaction between GRP94 and
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CTAl: Hsp90 bound to CTAl with a KD of 7 nM, whereas
GRP94 bound to CTAl with a KD of 292 nM (FIG. 18 and
Table 2). The specific, high-affinity interaction between
Hsp90-ATP and CTAl indicated that Hsp90 could be
involved with the CT intoxication process.
To detect a functional role for Hsp90 in CT intoxication,
CT toxicity assays were performed in the presence or absence
of GA (FIG. 19A). CT activates Gsa, which in tum stimulates
the activity of adenylate cyclase and the production of cAMP.
CHO cells treated with GA exhibited substantial resistance to
CT. In contrast, NECA-treated cells produced the same
response to CT as the untreated cells. GA-induced toxin
resistance was therefore due to the inactivation of Hsp90
rather than to the inactivation of GRP94. NECA-treated cells
were resistant to ricin, another AB toxin that uses the ERAD
system for A chain dislocation to the cytosol (FIG. 19B). This
observation was consistent with published results and demonstrated that NECA was functional at the concentration used
in our CT assay. Inactivation ofHsp90 thus provided cellular
protection against CT. Additional control experiments demonstrated that GA did not inhibit the forskolin-induced elevation of intracellular cAMP: cells treated with GA and forskolin produced 100±2% of the cAMP levels recorded for cells
treated with forskolin alone (n=3). Forskolin activates adenylate cyclase without the input of Gsa, so this observation
demonstrated that GA did not directly inhibit the production
of cAMP by adenylate cyclase.
GA also inhibited CT activity in the ilea! loop model of
intoxication (FIG. 19C). Surgically sealed sections of intestine were injected with 1 mg of CT in the absence or presence
of GA. Following a time interval, the CT-injected loop displayed the distended morphology indicative of water accumulation resulting from productive intoxication. In contrast,
substantially less fluid accumulation was observed in the loop
that was injected with both CT and 1 mM GA. GA derivatives
have also been evaluated as anti-cancer agents in phase I
clinical trials. The protective effect of GA in a physiological
model of intoxication suggests that it could also be used as a
therapeutic to prevent or treat cholera.
Toxin resistance can result from an inhibition of toxin
dislocation from the ER to the cytosol. To determine if GA
blocked toxin export to the cytosol, we used an established
dislocation assay to monitor the appearance of CTAl in the
cytosol of intoxicated HeLa cells (FIG. 4). Like CHO cells,
GA-treated HeLa cells were protected from CT (data not
shown). After a 30 minute exposure to CT at 4 ° C., HeLa cells
were chased for two hours at 37° C. in the absence of additional toxin. Separate organelle and cytosol fractions were
then collected from digitonin permeabilized cells. Control
experiments demonstrated the fidelity of our fractionation
protocol: Western blot analysis detected the majority of
Hsp90 in the supernatant (i.e., cytosolic) fraction, while protein disulfide isomerase (PDI), a soluble ER protein, was
found exclusively in the pellet fraction which contained the
intact ER and other membranes (FIG. 20A). The distributions
ofHsp90 and PDI were unaffected by treatment with GA or
NECA. In comparison to the untreated control cells, the distribution of CTAl in the cytosol of intoxicated cells was also
unaffected by NECA treatment. However, GA-treated cells
contained less cytosolic CTAl than either untreated or
NECA-treated cells. It thus appeared that Hsp90 function was
required for efficient passage of CTAl into the cytosol.
To strengthen our Western blot analysis with a more sensitive detection method, we employed the technique of SPR.
HeLa cells exposed to CT at 4° C. were again fractionated into
membrane and cytosolic components after a 2 hour chase at
37° C. In this experiment, the cytosolic fractions were per-

fused over a SPR sensor slide that had been coated with an
anti-CTA antibody (FIG. 20B). A negligible background signal was obtained from unintoxicated cells, whereas cells
intoxicated in the absence of drug treatment produced a
response that was equivalent the signal from the 0.1 ng/ml
CTA standard. Cells intoxicated in the presence of NECA
produced a response comparable to the response from cells
intoxicated in the absence of drug treatment. In contrast, cells
intoxicated in the presence of GA produced a weak SPR
signal that was much less than the signal obtained from the0.1
ng/ml CTA standard.
Recently, Hsp90 was shown to be involved with the renaturation of an unfolded protein that had passed from the cell
surface to the ER and from the ER to the cytosol. The Hsp90assisted refolding of denatured proteins may be linked to its
dislocation activity: by coupling dislocation with refolding,
Hsp90 would prevent the (re )folded CTAl protein from sliding back into the dislocation pore. This ratchet mechanism
would thus provide the driving force for CTAl dislocation.
Although a previous report had suggested that the ATP-dependent dislocation of CTAl does not require cytosolic factors, we and others have detected a membrane-associated
pool of Hsp90 which may have been purified with the
microsomal preparation used in that study. Our work clearly
shows that Hsp90 exhibits a high affinity interaction with
CTAl, and that the GA-induced disruption of this interaction
inhibits both CTAl dislocation and CT intoxication in vivo.
Hsp90 is also involved with ricin intoxication, although in
this case Hsp90 apparently prepares the catalytic toxin A
chain for proteasomal degradation. The GA-induced inactivation ofHsp90 thus allows ricinA chain to accumulate in the
cytosol and thereby generates cellular sensitization to ricin. In
contrast, we have shown that GA-treated cells are resistant to
CT. The dislocation of ricinA chain also involves GRP94 and
p97 whereas these proteins do not appear to be active in CTAl
dislocation. Thus, while both CTAl and ricinA chain exploit
ERAD for passage into the cytosol, distinct molecular events
are involved with the dislocation of the two toxins.
Hsp90 has been shown to maintain membrane-embedded
ERAD substrates in a soluble state and to help determine the
fate of misfolded proteins. This work establishes a new role
for Hsp90 in the extraction of a soluble ERAD substrate from
the ER. Methods, toxicity assays and dislocation assays performed in this section of our investigation are as described
above.
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CTAl exhibits a high affinity interaction with
Hsp90 and a lower affinity interaction with GRP94.
50

55

CTAl binding partner

ka(l/Ms)

kd (1/s)

KD(nM)

Hsp90
Grp94

9,929
1,537

7.8 x 10-5
4.5 x 10-4

7
292

On rates (ka), off rates (kd), and equilibrium dissociation
constants (KD) between CTAl and either Hsp90 or GRP94
were calculated from the data presented in FIG. 8.
TABLE3
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Cone (PBA in µM)

NearUV( 0 C.)

Far UV ( 0 c.)

0
100

29.0
36.0

31.0
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The transition temperature (midpoint of transition from
folded to unfolded conformations) for PTS 1 in the absence or
presence of PBA was calculated from far- and near-UV CD
data. Near-UV CD monitors changes in tertiary structure;
far-UV CD monitors changes in secondary structure. Higher
transition temperatures reflect increased protein stability.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
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The invention claimed is:
1. A method of inhibiting toxicity of a bacterial AB-type
toxin for a susceptible host, the method comprising contacting the toxin with a compound which interferes with unfolding of the toxin at the host's physiologic temperature, wherein
the toxin comprises cholera toxin or E. coli heat labile toxin
and wherein the compound is sodium 4-phenylbutyrate.
2. The method of claim 1, wherein the compound comprises sodium-4-phenylbutyrate (PBA) orally administered
to the host.
3. The method of claim 1, wherein the compound comprises sodium 4-phenylbutyrate (PBA) dissolved in the host's
fluids.
4. The method of claim 1, wherein the susceptible host
comprises mammalian cells.
5. The method of claim 1, wherein the susceptible host
comprises a human.
6. A method of inhibiting toxicity of a bacterial AB-type
ADP-ribosylating toxin for a susceptible host, the method
comprising contacting the toxin with a compound which
interferes with unfolding of the toxin in host cells or with
release of the toxin into host cells' cytosol, wherein the toxin
comprises cholera toxin and wherein the compound is sodium
4-phenylbutyrate.
7. The method of claim 6, wherein the compound comprises sodium-4-phenylbutyrate (PBA) orally administered
to the susceptible host.
8. The method of claim 6, wherein the compound comprises sodium 4-phenylbutyrate (PBA) dissolved in the susceptible host's fluids.
9. The method of claim 6, wherein the susceptible host
comprises mammalian cells.
10. The method of claim 6, wherein the susceptible host
comprises human cells.
11. The method of claim 6, wherein the susceptible host is
a human.
12. A method of treating a manmialian cell intoxicated with
a bacterialAB-typeADP-ribosylating toxin, the method comprising administering to the cell a compound which interferes
with thermal unfolding of the toxin molecule in the cell,
wherein the toxin comprises cholera toxin or E. coli heat
labile toxin and wherein the compound is sodium 4-phenylbutyrate.
13. A method of treating a manmialian cell intoxicated with
a bacterialAB-typeADP-ribosylating toxin, the method comprising administering to the cell a compound which interferes
with endoplasmic reticulum export of the toxin into the cytosol, wherein the toxin comprises cholera toxin or E. coli heat
labile toxin and wherein the compound is sodium 4-phenylbutyrate.
14. A method of treating a manmialian host intoxicated
with a bacterial AB-typeADP-ribosylating toxin, the method
comprising administering to the host a compound of sodium4-phenylbutyrate (PBA), wherein the toxin comprises cholera toxin or E. coli heat labile toxin.
15. The method of claim 14, wherein the mammalian host
comprises one or more mammalian cells.
16. The method of claim 14, wherein the mammalian host
comprises a human host.
17. The method of claim 14, wherein administering further
comprises orally administering sodium 4-phenylbutyrate.
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